Irom Group Receives SOCIAL IMPACT Award at HAPPY WOMAN AWARD 2026

Irom Group Honored at HAPPY WOMAN AWARD 2026

On March 5, 2026, the Irom Group was distinguished with the SOCIAL IMPACT Award at the HAPPY WOMAN AWARD 2026 ceremony, held to celebrate International Women's Day. This accolade reflects the organization’s unwavering dedication to advancing healthcare through pharmaceutical development and promoting women’s active engagement in the workforce.

Founded in Chiyoda, Tokyo, Irom Group has established itself as a key player in supporting the development of pharmaceuticals, which is foundational for launching new treatments. Their commitment to enhancing medical standards and the overall health of society is critical, as they strive to deliver new therapies to patients as swiftly as possible through clinical trials.

The HAPPY WOMAN AWARD aims to honor individuals and organizations that contribute to female empowerment and gender equality, ultimately participating in the creation of a sustainable society. Recipients are selected based on categories such as social impact, empathy, and sustainability, set forth by the organizing committee and council members.

In their pursuit of innovation, Irom Group emphasizes their brand promise: "A future without worries." This ideology drives them to explore every possible avenue to ensure a hopeful and secure tomorrow through creative methodologies and advanced technology. Notably, their efforts in clinical trials are crucial for saving patients’ lives by facilitating the development of future medicines.

Within Irom Group, a supportive environment for diversity is underscored, as they prioritize the promotion of women in leadership roles. They have implemented flexible systems to accommodate changes in life stages and have enriched career development training programs.

Recognizing the importance of diverse talent in the medical sector, Irom Group has committed itself to building a workplace where skills and ambitions are fully realized, merging business activities with the promotion of women’s advancement. This synergy not only generates significant social value but also presents new career models for women in medical and research fields.

The award validates Irom Group’s continuous efforts. By actively recruiting and empowering women, they generate substantial societal impact, demonstrating that a diverse workforce is essential for business growth. The recognition received from the SOCIAL IMPACT Award underscores the group's commitment to fostering an environment where everyone can thrive.

As a comprehensive clinical development organization, Irom Group operates across several sectors, including SMO (Site Management Organization), CRDMO (Contract Research and Development Manufacturing Organization), and medical support services. They have developed one of the largest clinical trial networks in Japan, partnering with approximately 4,500 medical institutions to cover the entire process from new drug development to post-marketing studies.

Also notable is their CRDMO business, which focuses on the development of new medicines using innovative healthcare technologies, such as Sendai virus vector technology and iPS cell production. Irom Group continues to leverage its expertise to support every aspect of pharmaceutical research, development, and manufacturing.

In conclusion, through their commendable efforts, Irom Group affirms that the empowerment of women is not just a corporate initiative; it serves as a vital catalyst for transformative changes in the healthcare sector, promising a future where gender equality and healthcare advancement go hand in hand.

For more information about Irom Group, you can visit their official website: Irom Group.